First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study.

ABSTRACT:

Background

the role of chemotherapy in advanced malignant peripheral nerve sheath tumor (MPNST) is unclear.

Patients and methods

chemotherapy-naive soft tissue sarcomas (STS) patients treated on 12 pooled nonrandomized and randomized European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials were retrospectively analyzed. Clinical outcomes, overall survival, progression-free survival (PFS) and response were determined for MPNST and other STS histotypes and compared. Additionally, prognostic factors within the MPNST population were defined. Studied cofactors were demographics, sarcoma history, disease extent and chemotherapy regimen.

Results

after a median follow-up of 4.1 years, 175 MPNST out of 2675 eligible STS patients were

SUBMITTER: Kroep JR 

PROVIDER: S-EPMC3003614 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature